CSL Behring aims to identify, develop and commercialize important new biotherapeutic products that save lives by preventing or treating serious medical conditions, including rare bleeding disorders. We are committed to significantly investing in our future research and development (R&D) portfolio and capabilities in the area of coagulation, including plasma replacement treatments and therapeutic proteins using recombinant technology. An overview of planned, current and finalized clinical trials may be found on clinicaltrials.gov. We also encourage independent research within the area of bleeding disorders by providing study grants both globally and locally.
Details about clinical studies supported by CSL Behring
are available, including recruiting studies for bleeding disorders, cardiac surgery, and fibrinogen treatment.
Recombinant Factor Therapies
Research advances in our recombinant coagulation program have resulted in pre-clinical and clinical proof of principle data showing extended half-life for recombinant factor VIIa
fused to recombinant albumin (rVIIa-FP), recombinant Factor VIII-Single Chain (rVIII-SingleChain) and recombinant factor IX fused to recombinant albumin (rIX-FP).
This is an extract of CSL Behring research. Visit F1000.com for additional posters.
Quantitative whole body autoradiography (QWBA) study on the effect of albumin fusion on the biodistribution of recombinant factor rFIX
E Herzog, S Harris, A McEwen, I Pragst, G Dickneite, S Schulte, S Zollner F1000Posters 2014, 5: 106 (poster) Summary
Safety and Pharmacokinetics of a Recombinant Fusion Protein-Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers
A Veldman F1000Posters 2014, 5: 105 (poster)
N-Glycosylation of rVIII-SingleChain, a novel recombinant single-chain factor VIII
S Schmidbauer, R Witzel, L Robbel, T Weimer, H Metzner, S Schulte F1000Posters 2014, 5: 134 (poster)
Pre-clinical safety and prolonged pharmacokinetic/pharmacodynamic (PK/PD) properties of a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
S Zollner, D Schurmann, F Kaspereit, W Krege, ..., J Muller-Cohrs, I Pragst, G Dickneite, S Schulte
F1000Posters 2014, 5: 124 (poster)
Pre-clinical pharmacokinetic/pharmacodynamic (PK/PD) characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII
S Zollner, E Raquet, A Feussner, J Müller-Cohrs, ..., T Weimer, I Pragst, G Dickneite, S Schulte
F1000Posters 2014, 5: 152 (poster) Summary
3/6/2015 4:19 PM